Is the business good?
How good a business is BRKR?
Bruker Corporation earns 0.92% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
0.92%
Return on invested capital · cost of capital 9.0% · 8.1 points below what the capital costs: growth destroys value
- Operating margin
- 1.4%
Operating margin · Medical Devices median 11% · 12 months to Q1 2026
- Share count, year on year
- +0.53%
Share count, year on year · flat: no meaningful dilution
- R&D as % of revenue
- 12%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 12% |
| FY2021 | 17% |
| FY2022 | 17% |
| FY2023 | 15% |
| FY2024 | 7.5% |
| FY2025 | 2.0% |
Details›
- Gross margin12 months to Q1 2026
- 45%
- Operating margin12 months to Q1 2026
- 1.4%
- Net margin12 months to Q1 2026
- −0.34%
- Free cash flow margin
- 1.5%
- R&D as % of revenue
- 12%
- Revenue, trailing twelve months
- $3.46B
- Free cash flow, trailing twelve months
- $51M
- Net income, trailing twelve months
- −$12M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 0.92%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.